BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 12.04.2022 | 07:00

BB Biotech AG concludes its share buyback program and launches a new buyback program

DGAP-News: BB BIOTECH AG / Key word(s): Share Buyback
12.04.2022 / 07:00
The issuer is solely responsible for the content of this announcement.

Media Release of April 12, 2022


BB Biotech AG concludes its share buyback program and launches a new buyback program

Yesterday, April 11, 2022, BB Biotech AG concluded the share buyback program it had initiated on April 12, 2019. During this period no registered shares were repurchased via a second trading line.

The Board of Directors passed a motion to launch a new share repurchase program immediately after the conclusion of this buyback program. Under the new share buyback program, BB Biotech AG is authorized to repurchase up to 10% of its shares (5 540 000 shares) over a period of 36 months. This decision marks a continuation of the payout policy introduced in 2013.


For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch


www.bbbiotech.com

Company profile

BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world's largest investors in this sector. BB Biotech relies on the long-standing experience of its distinguished Board of Directors and the investment research skills of the experienced investment management team of Bellevue Asset Management AG when making its investment decisions.

Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.



12.04.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

ISA gAG: Attraktive Wandelanleihe

Die International School Augsburg begibt Wandelanleihe als weiteren Finanzierungsbaustein des geplanten Schulneubaus; unserer Einschätzung nach liegen attraktive Konditionen vor und die Anleihe ist von der ISA gAG solide finanzierbar; das Wertpapier ist aus unserer Sicht sowohl für das Unternehmen als auch für die Investoren ein attraktives Investment.

Events im Fokus

Termine 2022

12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie

News im Fokus

Allianz SE: Allianz erzielt ein operatives Ergebnis von 3,5 Milliarden Euro im zweiten Quartal - Konzern bestätigt Ausblick für das Gesamtjahr

05. August 2022, 06:59

Aktueller Webcast

Nordex SE

Conference Call 15.08.2022 (Webcast)

15. August 2022

Aktuelle Research-Studie

GK Software SE

Original-Research: GK Software SE (von Montega AG): Kaufen

05. August 2022